IBEX 35
10.854,70 -17,30 (-0,16%) Euro Stoxx 50
4.921,48 +30,87 (+0,63%) Dólar/Euro
1,0765 +0,0038 (+0,36%) Petróleo Brent
82,82 -0,85 (-1,02%) Oro
2.310,10 +0,50 (+0,02%) Bitcoin EUR
59.570,71 +4.738,98 (+8,64%)
TaiMed Biologics Inc. (4147.TWO)
TaiMed Biologics Inc.
No. 607, Ruiguang Road
3rd Floor Neihu District
Taipei 11492
Taiwan
886 2 2658 0058
https://www.taimedbiologics.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Chin-Ming Chang Ph.D. | President & CEO | N/A | N/A | N/A |
| Dr. David D. Ho M.D. | Scientific Co-Founder, Chief Scientific Advisor and Board Director | N/A | N/A | 1953 |
| Dr. Ing-Wen Tsai Ph.D. | Co-Founder | N/A | N/A | N/A |
| Dr. Lan-Bo Chen Ph.D. | Co-Founder | N/A | N/A | N/A |
| Mr. Jack Chen | CFO & Chief of Corporate Governance | N/A | N/A | N/A |
Descripción
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. It develops and markets Ibalizumab (TMB-355) Intravenous Infusion, a humanized monoclonal antibody for the treatment of HIV-1 infection. It is also developing TMB-355 Intravenous Push, a humanized monoclonal antibody for the treatment of HIV-1 infection; TMB-355 Intramuscular Injection, a humanized monoclonal antibody intramuscular injection, which is in Phase III clinical trials for treating HIV-1; TMB-365, an anti-CD4 recombinant humanized monoclonal antibody, which completed Phase I clinical trials for treating HIV infections; and TMB-365/TMB-380, a neutralizing HIV-1 antibody. The company was incorporated in 2007 and is headquartered in Taipei, Taiwan.
Gobierno corporativo
El ISS Governance QualityScore de TaiMed Biologics Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
